This IMA test was developed to measure the amount of ischemia-modified albumin (IMA) in the blood. However, the test was never widely used and is no longer available for clinical use in the U.S. IMA was thought to be a promising cardiac biomarker, and a version of the test was approved by the FDA to help rule out cardiac ischemia in people with chest pain whose diagnosis was not clear